Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Protara Therapeutics (Nasdaq: TARA) said management will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics (Nasdaq: TARA) said management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:45 pm PT in San Francisco.
A live webcast will be available via the company’s Events and Presentations page at https://ir.protaratx.com and the webcast will be archived for a limited time after the presentation.
Details
News Market Reaction – TARA
On Jan 7, the day this news came out, TARA closed 11.13% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2026
- Scheduled conference presentation date
- Presentation time
- 3:45 pm PT
- Scheduled presentation time in San Francisco
Historical Context
-
Multiple FDA designations for TARA-002 in pediatric lymphatic malformations.
-
Closing of $75M underwritten public offering to fund clinical programs.
-
Pricing of $75M offering at $5.75 per share with underwriters’ option.
-
Announcement of proposed $75M public offering under existing shelf.
-
Updated Phase 2 ADVANCED-2 data with high CR rates and FDA feedback.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco.
A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.